title: Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis.
abstract: OBJECTIVE
  To assess treatment discontinuation rates with selective serotonin reuptake inhibitors compared with tricyclic antidepressants.
  
  
  METHODS
  Meta-analysis of 62 randomised controlled trials.
  
  
  METHODS
  6029 patients with major unipolar depression.
  
  
  METHODS
  Pooled risk ratios for drop out rates with respect to all cases of discontinuation and those due to side effects and treatment failure.
  
  
  RESULTS
  The total discontinuation rate was 10% lower with selective serotonin reuptake inhibitors than with tricyclic antidepressants (risk ratio 0.90; 95% confidence interval 0.84 to 0.97) and the drop out rate due to side effects was 25% lower (risk ratio 0.75; 0.66 to 0.84). There was no significant difference between drug classes in the drop out rates for treatment failure. The risk ratios for drop out did not differ significantly between individual selective serotonin reuptake inhibitors.
  
  
  CONCLUSIONS
  Selective serotonin reuptake inhibitors are better tolerated than tricyclic antidepressants as measured by total numbers of drop outs. The definite advantage to selective serotonin reuptake inhibitors is explained by fewer drop outs due to side effects. The overall difference, however, is comparatively small and may not be clinically relevant. Analyses of cost effectiveness should not overestimate the advantage to selective serotonin reuptake inhibitors.
authors.affiliation: Department of Psychiatry, University of Manchester.
authors.forename: I M
authors.initials: IM
authors.lastname: Anderson
authors.forename: B M
authors.initials: BM
authors.lastname: Tomenson
mesh_terms: D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003866:Depressive Disorder / Q000188:drug therapy*; D006801:Humans; D016017:Odds Ratio; D010352:Patient Dropouts; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D017211:Treatment Failure; D016312:Treatment Refusal
chemical_list: D000929:Antidepressive Agents, Tricyclic; D017367:Selective Serotonin Reuptake Inhibitors